Max Nisen

Just 18 months ago, Moderna Inc. was an early-stage biotechnology company working on a new way of making vaccines worth $6.5 billion. Today, after it developed and delivered one of the fastest-arriving and most effective shots against Covid-19, Moderna’s market value is approaching $100 billion. …

The Food and Drug Administration is already limiting one of the most controversial drug approvals in its 115-year history. The medication is Biogen Inc.'s Alzheimer's treatment Aduhelm, which won clearance last month despite mixed evidence and expert objections. The agency initially approved…

More than half a million Americans die of cancer each year, matching the toll of Covid-19 to date on an annual basis and making it one of the nation's biggest killers. But now there’s hope that a simple blood test could change that by detecting tumors earlier when they’re easier to treat. …

When the US Food and Drug Administration approved Biogen Inc.'s controversial Alzheimer's drug Aduhelm earlier this month without firm evidence that the drug helps patients, it created concern that other unproven treatments might follow. That scenario is already here. Eli Lilly & Co. announced…

The world is spoiled by Covid vaccine success. Speedily developed shots have proved highly and even exceptionally effective. That made weak results revealed late Wednesday by Germany’s CureVac about its mRNA vaccine especially disappointing. Previously hyped by Elon Musk's repeated endorsement and…

Research and manufacturing delays have dogged the arrival of a Covid-19 vaccine from Novavax Inc., one of only six selected by the US government's Operation Warp Speed for a large order. At one point in May, the company’s shares were down 62% from a February high. On Monday, though, Novavax took a…

"Follow the science" has been a consistent refrain during the pandemic, and it's usually a core mandate of the Food and Drug Administration in evaluating medicines. But when it came to one of the agency's most consequential decisions — the approval Monday of Biogen Inc.'s controversial Alzheimer's…

There are more than 10 effective Covid-19 vaccines in use around the world, so it's easy to forget those still in development. That's a mistake. These candidates may be taking longer to arrive, but they're essential to the pandemic fight. Most of the world is still unvaccinated, keeping the virus…

Max Nisen and Sam Fazeli, who cover the pharmaceutical industry for Bloomberg Opinion and Bloomberg Intelligence, answered questions about Covid-19 vaccine trial data released early Monday by AstraZeneca Plc and the University of Oxford. The dialog has been edited and condensed. Astra and Oxford…

The world now seems likely to have at least two effective vaccines against Covid-19 with Monday's announcement of positive early data from Moderna Inc.’s 30,000-person clinical trial. The result comes a week after Pfizer Inc. and BioNTech SE revealed a protection rate of more than 90% protection…